BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN BEGIN:VEVENT UID:723@biocityturku.fi DTSTART;TZID=Europe/Helsinki:20250204T140000 DTEND;TZID=Europe/Helsinki:20250204T150000 DTSTAMP:20250127T101623Z URL:https://biocityturku.fi/events/immunology-seminar-7/ SUMMARY:Immunology Seminar DESCRIPTION:4th February at 14:00-15:00\nOnline event\nin Zoom\n\nDr. Carlo s Rogério Figueiredo\, University of Turku\nNew Mechanisms of Immunosuppr ession in Melanoma: Implications for Rational Immunotherapy Innovation\n\n Host: Professor Riitta Lahesmaa ( rilahes@utu.fi )\n\nLink to the online s eminar: https://utu.zoom.us/j/68365123447\n\nImmunology seminar series is jointly organised by the Finnish Society for Immunology\, InFLAMES Flagshi p and Turku Bioscience. For further information contact Anne Lahdenperä ( ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi)\, University of Turku.\ n\n \;\n\nDr. Carlos Rogério Figueiredo is a Principal Investigator a nd Docent of Immunology at the University of Turku\, with a focus on cance r immunology and resistance to immunotherapy. Rogerio did his PhD in Immun ology &\; Microbiology in the Federal University of São Paulo\, Brazil \, in 2015. Postdoctoral Fellowships Rogerio did in translational oncology in the University of Liverpool and in Immuno-oncology in the University o f Turku. His research explores the molecular mechanisms underlying immunos uppression\, leading to cold tumor formation and poor responses to current immunotherapies. As the leader of the Medical Immuno-Oncology Research Gr oup (MIORG) in Finland\, he conducts integrative multi-omic studies to ide ntify novel biomarkers to advance prognostication tools and evaluate their functional roles in antitumor immune responses. This work supports eviden ce-based insights for rational immunotherapy innovation\, with a primary f ocus on cutaneous and ocular melanoma models. Rogerio is the winner of Sca ndinavian Society for Immunology (SSI) Young Investigator Award year 2024. \n\n \;\n\nSelected publications\n\nFigueiredo CR\, Azevedo RA\, Mousd ell S\, Resende-Lara PT\, Ireland L\, Santos A\, Girola N\, Cunha RLOR\, S chmid MC\, Polonelli L\, Travassos LR\, Mielgo A. Blockade of MIF-CD74 Sig nalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma. Front Immunol. 2018 May 23\;9:1132. doi: 10.3389/fimmu.2018.01132.\n\nFigueiredo CR\, Kalirai H\, Sacco JJ\, A zevedo RA\, Duckworth A\, Slupsky JR\, Coulson JM\, Coupland SE. Loss of B AP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma\, with implications for immunotherapy development. J Patho l. 2020 Apr\;250(4):420-439. doi: 10.1002/path.5384.\n\nMatareed M\, Maran ou E\, Koskela SA\, Mehmood A\, Kalirai H\, Coupland SE\, Figueiredo CR.    Novel prognostication biomarker adipophilin reveals a metabolic shift i n uveal melanoma and new therapeutic opportunities. J Pathol. 2023 Jun\;26 0(2):203-221. doi: 10.1002/path.6076.\n\nWang MM\, Coupland SE\, Aittokall io T\, Figueiredo CR. Resistance to immune checkpoint therapies by tumour- induced T-cell desertification and exclusion: key mechanisms\, prognostica tion and new therapeutic opportunities. Br J Cancer. 2023 Oct\;129(8):1212 -1224. doi: 10.1038/s41416-023-02361-4.\n\nLangguth M\, Maranou E\, Koskel a SA\, Elenius O\, Kallionpää RE\, Birkman EM\, Pulkkinen OI\, Sundvall M\, Salmi M\, Figueiredo CR.  TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity. Gen es Immun. 2024 Jun\;25(3):188-200. doi: 10.1038/s41435-024-00274-7. ATTACH;FMTTYPE=image/jpeg:https://biocityturku.fi/wp-content/uploads/Roger io-scaled.jpg CATEGORIES:Other events END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Helsinki X-LIC-LOCATION:Europe/Helsinki BEGIN:STANDARD DTSTART:20241027T030000 TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET END:STANDARD END:VTIMEZONE END:VCALENDAR